P3 Health Partners, Inc.

As of February 9, 2022, P3 Health Partners, Inc. is considered risky and overvalued due to negative financial metrics and significant underperformance against the S&P 500, with a year-to-date return of -32.68%.

As of February 9, 2022, P3 Health Partners, Inc. is considered risky and overvalued due to poor financial ratios, including a Price to Book Value of 0.75, an EV to Sales ratio of 0.12, and negative profitability metrics, while significantly underperforming against peers and the S&P 500.

As of June 11, 2025, the market trend has shifted to bearish, with strong bearish signals from moving averages and Dow Theory, despite a mildly bullish MACD, indicating significant weakness compared to the S&P 500.

P3 Health Partners, Inc. is a micro-cap company in the miscellaneous industry, reporting net sales of $373 million and a net profit loss of $44 million as of March 2025. Key financial metrics include a market cap of $45.21 million, a debt equity ratio of 2.07, and a return on equity of -509.38%.

As of Jun 18, P3 Health Partners, Inc. has a market capitalization of 45.21 million and reported net sales of 1,485.20 million, with a net profit loss of 305.02 million. The company's balance sheet shows shareholder's funds of 75.94 million and total assets of 783.42 million.